Belgian drugmaker Solvay Pharmaceuticals has signed an agreement with HUYA Bioscience International, a company specialized in enabling and accelerating global co- development of novel biopharmaceutical product opportunities originating in China. Solvay will gain access to HUYA's comprehensive Chinese molecule portfolio, focusing specifically on compounds in the cardiovascular area. As some are already in advanced stages of development in China, the partnership will help Solvay speed up its early discovery activities. Financial terms of the deal were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze